938443-23-3

Basic information

• Product Name: Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, rel-
• Synonyms: Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, rel-;(2S,6R)-4-(7-chloro-4-morpholinopyrido[2,3-d]pyrimidin-2-yl)-2,6-dimethylmorpholine;rel-7-Chloro-2-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-4-(4-morpholinyl)pyrido[2,3-d]pyrimidine
• CAS NO: 938443-23-3
• Molecular Formula: C₁₇H₂₂ClN₅O₂
• Molecular Weight: 363.84188
• Mol File: 938443-23-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 567.9°C at 760 mmHg
• Flash Point: 297.2°C
• Appearance: /
• Density: 1.291g/cm³
• Vapor Pressure: 6.53E-13mmHg at 25°C
• Refractive Index: 1.599
• PKA: 5.00±0.30(Predicted)
• CAS DataBase Reference: Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, rel-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, rel-(938443-23-3)
• EPA Substance Registry System: Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, rel-(938443-23-3)

Safety Data

• Hazardous Substances Data: 938443-23-3(Hazardous Substances Data)

Usage

General Description

The chemical compound Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, rel- is a heterocyclic compound with a pyridine and pyrimidine ring structure. It contains a chlorine atom and two morpholine groups, along with two methyl groups in a stereo-specific configuration. Pyrido[2,3-d]pyriMidine, 7-chloro-2-[(2R,6S)-2,6-diMethyl-4-Morpholinyl]-4-(4-Morpholinyl)-, rel- is likely to exhibit bioactive properties due to its complex structure and potentially interacting moieties. Further research is needed to determine its specific biological activities and potential applications in the fields of pharmaceuticals or materials science.

InChI:InChI=1/C17H22ClN5O2/c1-11-9-23(10-12(2)25-11)17-20-15-13(3-4-14(18)19-15)16(21-17)22-5-7-24-8-6-22/h3-4,11-12H,5-10H2,1-2H3/t11-,12+

Upstream product

• 58584-92-2 2-amino-6-chloronicotinic acid 
• 938443-20-0 2,4,7-trichloropyrido[2,3-d]pyrimidine 
• 938443-19-7 7-chloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 45597-00-0 (3R,5S)-3,5-dimethylmorpholine 
• 938443-21-1 4-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)morpholine 
• 141-91-3 cis-2,6-dimethylmorpholine 

Downstream Products

• 938443-29-9 7-(3-chloromethyl-4-methoxy-phenyl)-2-((2S,6R)-2,6-dimethyl-morpholin-4-yl)-4-morpholin-4-yl-pyrido[2,3-d]pyrimidine 
• 1424432-35-8 C₂₆H₃₄N₆O₃ 
• 1424432-36-9 C₂₅H₃₂N₆O₂ 
• 1424432-37-0 C₂₆H₃₄N₆O₂ 
• 938440-64-3 KU-63794 

Relevant articles and documents

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21).

2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

There is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula (1), and the use of a compound of Formula (1) as a medicament and in the treatment of cancer